Publicaciones en las que colabora con Enrique Grande Pulido (19)

2022

  1. Erratum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation (Oncotarget. (2020) 11 (2137–2140) DOI: 10.18632/oncotarget.27598)

    Oncotarget

2021

  1. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

    Frontiers in Endocrinology, Vol. 12

  2. Novel tyrosine kinase targets in urothelial carcinoma

    International Journal of Molecular Sciences, Vol. 22, Núm. 2, pp. 1-28

2020

  1. Braf mutated colorectal cancer: New treatment approaches

    Cancers, Vol. 12, Núm. 6, pp. 1-15

  2. Current and future role of tyrosine kinases inhibition in thyroid cancer: From biology to therapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 14, pp. 1-29

  3. Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation

    Oncotarget, Vol. 11, Núm. 22, pp. 2137-2140

2019

  1. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: A pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    BMC Cancer, Vol. 19, Núm. 1

  2. Targeting tyrosine kinases in renal cell carcinoma: “New bullets against old guys”

    International Journal of Molecular Sciences, Vol. 20, Núm. 8

2015

  1. Papel de la nutrición parenteral en pacientes oncológicos con oclusión intestinal y carcinomatosis peritoneal

    Nutricion Hospitalaria, Vol. 32, Núm. 3, pp. 1222-1227

  2. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993

2014

  1. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?

    Critical Reviews in Oncology/Hematology, Vol. 92, Núm. 2, pp. 83-106

2013

  1. A significant response to sunitinib in a patient with anaplastic thyroid carcinoma

    Journal of Research in Medical Sciences, Vol. 18, Núm. 7, pp. 622-624

2012

  1. New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies

    Expert Review of Anticancer Therapy, Vol. 12, Núm. 4, pp. 457-467

2011

  1. Biosimilars: What they are and their use in oncology

    Cancer and Chemotherapy Reviews, Vol. 6, Núm. 3, pp. 141-148

  2. Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma

    Anti-Cancer Drugs, Vol. 22, Núm. 8, pp. 817-821

  3. Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor

    Anti-Cancer Drugs, Vol. 22, Núm. 5, pp. 477-479

2010

  1. Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)

    Clinical and Translational Oncology, Vol. 12, Núm. 7, pp. 481-492

  2. Antineoplastic drug-induced neutropenia: Use of granulocyte colony stimulating factors

    Farmacia Hospitalaria, Vol. 34, Núm. SUPPL. 1, pp. 8-11

  3. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: Sunitinib

    Anti-Cancer Drugs, Vol. 21, Núm. SUPPL.1